Urinary Tract Cancer Clinical Trial
Official title:
An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression
This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy. The anticipated time on study treatment is until disease progression.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02928406 -
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
|
Phase 3 | |
| Recruiting |
NCT05544552 -
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02379429 -
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
|
||
| Recruiting |
NCT05038657 -
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
|
Phase 2 | |
| Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
| Recruiting |
NCT04718948 -
Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
|
||
| Completed |
NCT02006667 -
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
|
Phase 2 | |
| Completed |
NCT03410641 -
Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study
|
N/A | |
| Completed |
NCT03013920 -
CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma
|